Next Science Limited (NXSCF)
Next Science Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Sydney, NSW, AU. The stock last traded at $0.00, down 93.75% on the session, giving a market capitalisation of $292,625. On trailing twelve-month figures it carries a trailing P/E of -0.03, a net margin of -46.4%. Its beta of 1.69 implies it has historically moved more than the broad market.
Next Science Limited operates as a medical technology firm, dedicated to the research, development, and commercialization of innovative solutions aimed at mitigating the detrimental effects of biofilms on human health. The company serves markets in both the United States and Australia, building its product portfolio on its proprietary Xbio Technology platform. Among its key offerings are: SURGX: An antimicrobial gel employed for managing surgical infections. BACTISURE: A specialized wound lavage designed to eliminate biofilm. BlastX: An antimicrobial wound gel that not only eradicates bacteria within the gel but also wards off recolonization, all while maintaining an optimal moist healing environment. XPERIENCE: A no-rinse antimicrobial solution developed specifically to deter surgical site infections. Established in 2012, Next Science Limited maintains its primary operational base in Chatswood, Australia.
Next Science Limited is most often compared with the following Healthcare names: